21 research outputs found
Monitoring of Cardiorespiratory Parameters in Rats—Validation Based on Pharmacological Stimulation
The methods used in preclinical studies should minimize the suffering and the number of animals but still provide precise and consistent results enabling the introduction of drug candidates into the phase of clinical trials. Thus, we aimed to develop a method allowing us to perform preliminary safety and toxicity studies of candidates for human medicines, while reducing the number of animals. We have devised a method based on a combination of two devices: Plugsys (Transonics System Inc., Ithaca, NY, USA) and PhysioSuite (Kent Scientific Corporation, Torrington, CT, USA), which allow simultaneous registration of nine circulatory and respiratory parameters, and body temperature. Vehicle and adrenaline, or nitroglycerin, as reference substances were administered into the right femoral vein of Wistar rats. Physiological conditions were registered over 60 min after drug administration by measuring systolic, diastolic and mean blood pressure, heart rate (HR), blood perfusion of paw vessels, blood oxygen saturation, respiratory rate, average and peak exhaled CO2, and body temperature. Blood pressure was measured by cannula placed in the left common carotid artery and connected to the pressure transducer (Plugsys). The other parameters were measured by the PhysioSuite. Adrenaline-induced immediate dose-related hypertension and nitroglycerin hypotension were correlated with the change in blood perfusion. They both increased HR. Adrenaline decreased blood oxygen saturation and slightly affected respiratory parameters, while nitroglycerin caused a progressive increase in respiratory rate and a decrease in the peak of exhaled CO2. Our method may become an inseparable part of the preliminary safety and toxicity studies of tested drugs, while being an important step towards improving animal welfare
Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401
An increase in the peripheral synthesis of serotonin and kynurenine, observed during the chronic kidney disease (CKD) course, is negatively associated with bone health. Serotonin and kynurenine are connected by the common precursor, tryptophan. LP533401 is an inhibitor of peripheral serotonin synthesis. This study aimed to establish if the inhibition of serotonin synthesis by LP533401 may affect the kynurenine pathway activity in bone tissue and its potential consequence with regard to osteogenesis and bone mineral status. Nephrectomized rats were treated with LP533401 at a dose of 30 and 100 mg/kg daily for eight weeks. Tryptophan and kynurenine concentrations were determined, and tryptophan 2,3-dioxygenase (TDO) expression was assessed. We discovered the presence of a TDO-dependent, paracrine kynurenic system in the bone of rats with CKD. Its modulation during LP533401 treatment was associated with impaired bone mineral status. Changes in TDO expression affecting the kynurenine pathway activity were related to the imbalance between peripheral serotonin and 25-hydroxyvitamin D. There were also close associations between the expression of genes participating in osteoblastogenesis and activation of the kynurenine pathway in the bones of LP53301-treated rats. Our results represent the next step in studying the role of tryptophan metabolites in renal osteodystrophy
A link between central kynurenine metabolism and bone strength in rats with chronic kidney disease
Background Disturbances in mineral and bone metabolism represent one of the most complex complications of chronic kidney disease (CKD). Serotonin, a monoamine synthesized from tryptophan, may play a potential role in bone metabolism. Brain-derived serotonin exerts a positive effect on the bone structure by limiting bone resorption and enhancing bone formation. Tryptophan is the precursor not only to the serotonin but also and primarily to kynurenine metabolites. The ultimate aim of the present study was to determine the association between central kynurenine metabolism and biomechanical as well as geometrical properties of bone in the experimental model of the early stage of CKD. Methods Thirty-three Wistar rats were randomly divided into two groups (sham-operated and subtotal nephrectomized animals). Three months after surgery, serum samples were obtained for the determination of biochemical parameters, bone turnover biomarkers, and kynurenine pathway metabolites; tibias were collected for bone biomechanical, bone geometrical, and bone mass density analysis; brains were removed and divided into five regions for the determination of kynurenine pathway metabolites. Results Subtotal nephrectomized rats presented higher serum concentrations of creatinine, urea nitrogen, and parathyroid hormone, and developed hypocalcemia. Several biomechanical and geometrical parameters were significantly elevated in rats with experimentally induced CKD. Subtotal nephrectomized rats presented significantly higher kynurenine concentrations and kynurenine/tryptophan ratio and significantly lower tryptophan levels in all studied parts of the brain. Kynurenine in the frontal cortex and tryptophan in the hypothalamus and striatum correlated positively with the main parameters of bone biomechanics and bone geometry. Discussion In addition to the complex mineral, hormone, and metabolite changes, intensified central kynurenine turnover may play an important role in the development of bone changes in the course of CKD
Elevated Levels of Peripheral Kynurenine Decrease Bone Strength in Rats with Chronic Kidney Disease
The diagnosis and treatment of bone disorders in patients with chronic kidney disease (CKD) represent a clinical challenge. CKD leads to mineral and bone complications starting early in the course of renal failure. Recently, we have observed the positive relationship between intensified central kynurenine turnover and bone strength in rats with subtotal 5/6 nephrectomy (5/6 Nx)-induced CKD. The aim of the present study was to determine the association between peripheral kynurenine pathway metabolites and bone strength in rats with 5/6 Nx-induced CKD. The animals were sacrificed 1 and 3 months after 5/6 Nx or sham operation. Nephrectomized rats presented higher concentrations of serum creatinine, urea nitrogen, and parathyroid hormone both 1 and 3 months after nephrectomy. These animals revealed higher concentrations of kynurenine and 3-hydroxykynurenine in the serum and higher gene expression of aryl hydrocarbon receptor (AhR) as a physiological receptor for kynurenine and AhR-dependent cytochrome in the bone tissue. Furthermore, nephrectomy significantly increased the number of osteoclasts in the bone without affecting their resorptive activity measured in serum. These changes were particularly evident in rats 1 month after 5/6 Nx. The main bone biomechanical parameters of the tibia were unchanged between nephrectomized and sham-operated rats but were significantly increased in older compared to younger animals. A similar trend was observed for geometrical parameters measured with calipers, bone mineral density based on Archimedes' method and image of bone microarchitecture obtained from micro-computed tomography analyses of tibial cortical bone. In nephrectomized animals, peripheral kynurenine levels correlated negatively with the main parameters of bone biomechanics, bone geometry, and bone mineral density values. In conclusion, our data suggest that CKD-induced elevated levels of peripheral kynurenine cause pathological changes in bone structure via AhR pathway. This finding opens new opportunities for the treatment/prevention of osteoporosis in CKD
Anticoagulant Properties of Poly(sodium 2‑(acrylamido)-2-methylpropanesulfonate)-Based Di- and Triblock Polymers
Di- and triblock copolymers with
low dispersity of molecular weight
were synthesized using radical addition–fragmentation chain
transfer polymerization. The copolymers contained anionic poly(sodium
2-acrylamido-2-methylpropanesulfonate) (PAMPS) block as an anticoagulant
component. The block added to lower the toxicity was either poly(ethylene
glycol) (PEG) or poly(2-(methacryloyloxy)ethyl phosphorylcholine)
(PMPC). The polymers prolonged clotting times both in vitro and in
vivo. The influence of the polymer architecture and composition on
the efficacy of anticoagulation and safety parameters was evaluated.
The polymer with the optimal safety/efficacy profile was PEG47-<i>b</i>-PAMPS108, i.e., a block copolymer with the degrees of
polymerization of PEG and PAMPS blocks equal to 47 and 108, respectively.
The anticoagulant action of copolymers is probably mediated by antithrombin,
but it differs from that of unfractionated heparin. PEG47-<i>b</i>-PAMPS108 also inhibited platelet aggregation in vitro
and increased the prostacyclin production but had no antiplatelet
properties in vivo. PEG47-<i>b</i>-PAMPS108 anticoagulant
activity can be efficiently reversed with a copolymer of PEG and poly((3-(methacryloylamino)propyl)trimethylammonium
chloride) (PMAPTAC) (PEG41-<i>b</i>-PMAPTAC53, HBC), which
may be attributed to the formation of polyelectrolyte complexes with
PEG shells without anticoagulant properties
Antithrombotic Effects of Pyridinium Compounds Formed from Trigonelline upon Coffee Roasting
Coffee
may exert a preventive effect on arterial thrombosis. Trigonelline
is one of the most abundant compounds in coffee that undergoes pyrolysis
upon roasting of coffee beans. The aim of the present study was to
identify pyridinium compounds formed upon trigonelline pyrolysis and
coffee roasting and to investigate the effect of three of them, i.e.,
1-methylpyridine and 1,3- and 1,4-dimethylpyridine, on experimentally
induced arterial thrombosis in rats. 1,3- and 1,4-dimethylpyridine
but not 1-methylpyridine inhibited arterial thrombus formation. 1,3-Dimethylpyridine
inhibited platelet aggregation and reduced fibrin formation in platelet-rich
plasma, whereas 1,4-dimethylpyridine increased the plasma level of
6-keto-PGF<sub>1α</sub>. 1,4-Dimethylpyridine slightly increased
rat tissue plasminogen activator plasma activity. In summary, we demonstrated
that pyridinium compounds display mild antithrombotic properties due
to stimulation by prostacyclin release (1,4-dimethylpyridine) and
inhibition of platelet aggregation (1,3-dimethylpyridine). Those pyridinium
compounds may, to some extent, be responsible for the beneficial effects
of coffee drinking
Evaluation of the immune response to the cationic polymers.
<p>Humoral immune response evaluation by ELISA on day 36 of the experiment. The levels of IgG specific toward different UFH inhibitors in individual mice presented as values of absorbance in ELISA test. The inserted graph shows mean ELISA signals corresponding to the levels of anti-protamine-, anti-Dex40-GTMAC2- or Dex40-GTMAC3-IgG present in sera of mice immunized with matching UFH-antidotes (gray bars) compared to the signals from sera of control mice treated with UFH alone (black bars). All sera applied in 1:100 dilution, b-P<0.01, Mann-Whitney test. Results are shown as mean ± SD, n = 5.</p
Effects of the cationic polymers on blood pressure in rats.
<p>MBP change registered 60 min after iv administration of Dex40-GTMAC2 (4.2 and 12.5 mg·kg<sup>-1</sup>), Dex40-GTMAC3 (2.5, 7.5, and 22.5 mg·kg<sup>-1</sup>), Dex6-GTMAC (9.6 and 28.8 mg·kg<sup>-1</sup>), GCD-GTMAC2 (10.8 and 32.4 mg·kg<sup>-1</sup>), and protamine (3.0 and 9.0 mg·kg<sup>-1</sup>) (A) and UFH (300 U·kg<sup>-1</sup>) followed by the injection of Dex40-GTMAC2 (12.5 mg·kg<sup>-1</sup>), Dex40-GTMAC3 (7.5 mg·kg<sup>-1</sup>), Dex6-GTMAC (9.6 mg·kg<sup>-1</sup>), GCD-GTMAC2 (10.8 mg·kg<sup>-1</sup>), and protamine (3.0 mg·kg<sup>-1</sup>) (B), a-P<0.05, b-P<0.01 vs. vehicle, Mann-Whitney test. Results are shown as mean ±SD, n = 4–6.</p